<DOC>
	<DOCNO>NCT01930604</DOCNO>
	<brief_summary>Hyperhidrosis define excessive sweating affect 2.8 % population . It show deleterious effect quality life measure use Dermatology Life Quality Index ( DLQI ) one widely use dermatology-specific quality life instrument . This comparable effect quality life patient severe psoriasis skin well nodulocystic acne patient treatment oral isotretinoin . The clinical effect Botulinum Toxin ( Btx ) A establish three randomize control trial ( RCT ) axillary hyperhidrosis . One RCT indicate positive effect palmar hyperhidrosis . Although increase evidence Btx A B similar effect hyperhidrosis part body ( ie hyperhidrosis face , trunk , groin foot ) report case-reports open study still great need control study . This carry randomize , double-blind , placebo-controlled study investigate clinical effect safety Btx A palmar , plantar inguinal ( groins/buttocks ) hyperhidrosis clinical effect safety Btx B craniofacial truncal hyperhidrosis , respectively . Besides use DLQI instrument also study Btx A/B elucidate impact treatment quality life use generic instrument , effect anxiety depressive symptom , sweat , patients´global assessment therapy .</brief_summary>
	<brief_title>Botulinum Toxin Treatment Craniofacial , Inguinal , Palmar , Plantar Truncal Hyperhidrosis</brief_title>
	<detailed_description />
	<mesh_term>Hyperhidrosis</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<mesh_term>rimabotulinumtoxinB</mesh_term>
	<criteria>Informed consent receive patient Informed consent receive patient´s parent ( patient &lt; 18 year ) Hyperhidrosis head , trunk , groins/buttocks , hand foot Age &gt; 16 year Patients must previously untreated Btx A/B If female , patient postmenopausal , surgically sterilize , willing use acceptable method birth control ( i.e . hormonal contraceptive , intrauterine device , diaphragm spermicide , condom* ) throughout study . If male female partner childbearing potential , willing use acceptable method birth control study duration study , female male , acceptable birth control must use least 3 month last dose study medication . * A condom alone consider acceptable method birth control . Two barrier method consider acceptable method birth control . Patients must DLQIscore ≥ 10 HDSSscore ≥ 3 Contraindication Btx Use aminoglycosides , tetracycline , spectinomycin , lincomycin , polymyxin muscle relaxant Pregnancy lactation Patients unwilling meet requirement protocol Other medical social reason exclusion discretion Investigator</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Palmar hyperhidrosis .</keyword>
	<keyword>Plantar hyperhidrosis .</keyword>
	<keyword>Inguinal ( groin buttock ) hyperhidrosis .</keyword>
	<keyword>Craniofacial hyperhidrosis .</keyword>
	<keyword>Truncal hyperhidrosis .</keyword>
</DOC>